CYNTRA Advanced Pigment Corrector
The strongest CYSTEAMINE N' TRANEXAMIC acid nano-formula cream to eliminate stubborn pigment.

Our small molecule approach aims at the very core of pigment cells with more safety and unparalleled efficacy to treat:

NanoMD CYNTRA Revolutionary Nano Technology




NanoMD CYNTRA Mechanism of Action

Cysteamine is known to be a potent depigmenting molecule.
Cysteamine can be targeted at pigment producing cells (melanocytes) and reprogram them to slow down the production of pigment (melanosomes).
This process is called melanogenesis inhibition.

Melanogenesis inhibition is not an "overnight" process.
Skin needs some time to "push out" and "shed off" previously produced pigment. With a quality clinical guidance and a satisfactory patient compliance, initial depigmenting can be observed after I month of therapy.

The best depigmenting results are typically observed after 3 months of therapy.
Cysteamine si proven to be a well-tolerated compound (human body creates Cysteamine from its own coenzyme A reserves). Therefore, a physician can recommend extending NanoMD® CyntraTM therapy beyond 3 months to promote ongoing management of hyperpigmentation.

Color-enhanced transmission electron micrograph of a pigment cell. The melanocyte in the image is in the connective tissue and its cytoplasm is crowded with melanosomes.
Clinical Case




The patient received a treatment cycle consisting of one 15 minute application each day for 30 days.
Images courtesy of Boston Sante, Inc. unless otherwise specified.
NanoMD CYNTRA Use and Indications
Cysteamine and tranexamic acid are proven to be well-tolerated compounds. With
quality clinical guidance and satisfactory patient compliance, initial depigmenting can be observed after I month of therapy. The full effect is typically achieved after 3 months. NanoMD® CyntraTM therapy can be extended beyond 3 months to promote ongoing management of hyperpigmentation.